ArticleOncogene2005
beta-Catenin activates the growth factor endothelin-1 in colon cancer cells.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 94 citations in OpenAlex.
- Decoding GPCR signaling reprogramming in cancer: molecular mechanisms and therapeutic implications.Molecular medicine (Cambridge, Mass.) · 2026Review
- Dissecting the boundary of quiescence and activation of murine melanocyte stem cells in the hair follicle niche.NPJ Regenerative medicine · 2026Review
- Research Progress of GPR137 in Malignant Tumors: A Review.OncoTargets and therapy · 2025Review
- Targeting the Endothelin-1 pathway to reduce invasion and chemoresistance in gallbladder cancer cells.Cancer cell international · 2023Article
- Endothelin-3 is epigenetically silenced in endometrioid endometrial cancer.Journal of cancer research and clinical oncology · 2023Article
- Systems analysis identifies endothelin 1 axis blockade for enhancing the anti-tumor effect of multikinase inhibitor.Cancer gene therapy · 2022Article
- Design, synthesis and evaluation of 4,7-disubstituted 8-methoxyquinazoline derivatives as potential cytotoxic agents targeting β-catenin/TCF4 signaling pathway.Translational oncology · 2022Article
- Endothelin-1 axes in the framework of predictive, preventive and personalised (3P) medicine.The EPMA journal · 2021Review
- NOTUM promotes thermogenic capacity and protects against diet-induced obesity in male mice.Scientific reports · 2021Article
- Blocking endothelin-1-receptor/β-catenin circuit sensitizes to chemotherapy in colorectal cancer.Cell death and differentiation · 2017Article
- Impaired activity of adherens junctions contributes to endothelial dilator dysfunction in ageing rat arteries.The Journal of physiology · 2017Article
- Roles of Wnt Target Genes in the Journey of Cancer Stem Cells.International journal of molecular sciences · 2017Review
- Functions of endothelin-1 in apoptosis and migration in hepatocellular carcinoma.Experimental and therapeutic medicine · 2017Article
- In Development-A New Paradigm for Understanding Vascular Disease.Journal of cardiovascular pharmacology · 2017Review
- Article
- Epigenetic silencing of endothelin-3 in colorectal cancer.International journal of immunopathology and pharmacology · 2016Article
- Colon cancer cell invasion is promoted by protein kinase CK2 through increase of endothelin-converting enzyme-1c protein stability.Oncotarget · 2015Article
- The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing.The Journal of experimental medicine · 2015Article
- The Gβ5 protein regulates sensitivity to TRAIL-induced cell death in colon carcinoma.Oncogene · 2015Article
- Canonical Wnt signaling induces vascular endothelial dysfunction via p66Shc-regulated reactive oxygen species.Arteriosclerosis, thrombosis, and vascular biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Endothelin-1 (EDN1) is a growth factor that is frequently produced by cancer cells and plays a critical role in tumorigenesis. However, the molecular mechanism controlling the expression of EDN1 in cancers is unknown. Constitutive activation of beta-catenin pathway is responsible for the initiation of the vast majority of colon cancers. Here we show that the EDN1 gene is directly regulated by beta-catenin in colon cancer cells. A specific DNA element within the EDN1 promoter is required for activation, and is associated with beta-catenin's cognate DNA binding partner, TCF4, in vivo. Inhibition of beta-catenin signaling results in lowered expression of EDN1, while enhancement of beta-catenin signaling leads to further activation of the gene. Significantly elevated EDN1 expression occurs in 80% of primary human colon cancers, consistent with it being a direct target of beta-catenin. Furthermore, EDN1 is able to rescue colon cancer cells from growth arrest and apoptosis resulting from inhibition of beta-catenin signaling, implicating a key role of EDN1 in promoting the oncogenic function of beta-catenin. These results indicate EDN1 overexpression as a major cause in colon cancers and reveal further details of the genetic programs responsible for tumorigenesis of colon cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.